Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.

Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern.